Cellectis, Allogene To Continue Strategic Cancer Immunotherapy Collaboration – Nasdaq
Nasdaq |
Cellectis, Allogene To Continue Strategic Cancer Immunotherapy Collaboration
Nasdaq (RTTNews.com) – Cellectis ( CLLS ) and Allogene Therapeutics Inc. said that Allogene intends to assume from Pfizer the global strategic collaboration to develop "off-the-shelf" CAR T immunotherapies for oncology. This agreement was initially formed … |
